These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 29191855

  • 1. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
    Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [Abstract] [Full Text] [Related]

  • 2. Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.
    Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, Wild D.
    J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
    [Abstract] [Full Text] [Related]

  • 3. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    Recent Results Cancer Res; 2013 Jun; 194():353-71. PubMed ID: 22918768
    [Abstract] [Full Text] [Related]

  • 4. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [Abstract] [Full Text] [Related]

  • 5. Quantitative 3D Assessment of 68Ga-DOTATOC PET/MRI with Diffusion-Weighted Imaging to Assess Imaging Markers for Gastroenteropancreatic Neuroendocrine Tumors: Preliminary Results.
    Adams LC, Bressem KK, Brangsch J, Reimann C, Nowak K, Brenner W, Makowski MR.
    J Nucl Med; 2020 Jul; 61(7):1021-1027. PubMed ID: 31862798
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
    Sharma A, Das CJ, Makharia GK, Arora G, Kumar R.
    Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
    [Abstract] [Full Text] [Related]

  • 7. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V, Tiling N, Denecke T, Brenner W, Plöckinger U.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [Abstract] [Full Text] [Related]

  • 8. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 10. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
    Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges JP, Salaun PY, Kerlan V, Bourhis D, Abgral R.
    Clin Nucl Med; 2021 Feb 01; 46(2):111-118. PubMed ID: 33234927
    [Abstract] [Full Text] [Related]

  • 11. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
    Flechsig P, Zechmann CM, Schreiweis J, Kratochwil C, Rath D, Schwartz LH, Schlemmer HP, Kauczor HU, Haberkorn U, Giesel FL.
    Eur J Radiol; 2015 Aug 01; 84(8):1593-1600. PubMed ID: 25999064
    [Abstract] [Full Text] [Related]

  • 12. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar 01; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 13. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
    Srp Arh Celok Lek; 2015 Mar 01; 143(1-2):108-15. PubMed ID: 25845263
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.
    Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, Lahner H, Führer D, Bockisch A, Herrmann K, Forsting M, Antoch G, Umutlu L.
    Eur Radiol; 2017 Oct 01; 27(10):4091-4099. PubMed ID: 28439648
    [Abstract] [Full Text] [Related]

  • 15. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors.
    Zhu W, Cheng Y, Jia R, Zhao H, Bai C, Xu J, Yao S, Huo L.
    J Nucl Med; 2021 Oct 01; 62(10):1398-1405. PubMed ID: 33579804
    [Abstract] [Full Text] [Related]

  • 16. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W, Hartmann H, Wiedemann B, Zöphel K, Luboldt HJ.
    Mol Imaging; 2010 Dec 01; 9(6):351-8. PubMed ID: 21084031
    [Abstract] [Full Text] [Related]

  • 17. Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study.
    Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, Jia R, Xu J, Huo L.
    J Nucl Med; 2020 Jun 01; 61(6):897-903. PubMed ID: 31676731
    [Abstract] [Full Text] [Related]

  • 18. Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study.
    Lin Z, Zhu W, Zhang J, Miao W, Yao S, Huo L.
    J Nucl Med; 2023 Sep 01; 64(9):1406-1411. PubMed ID: 37474267
    [Abstract] [Full Text] [Related]

  • 19. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of 68Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy.
    Lodge MA, Solnes LB, Chaudhry MA, Wahl RL.
    Mol Imaging Biol; 2021 Oct 01; 23(5):766-774. PubMed ID: 33829361
    [Abstract] [Full Text] [Related]

  • 20. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J.
    J Nucl Med; 2022 Mar 01; 63(3):376-383. PubMed ID: 34215673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.